 The FDA has signed off Tonix Pharmaceuticals Holding Corps NASDAQ: TNXP Investigational New Drug IND Application to initiate Phase 2 study of TNX-1900 for migraine. TNX-1900 is intranasal potentiated oxytocin designed for the prevention of migraine headaches in chronic migraineurs. 